Sarah L. Dallas

Sarah L. Dallas

Auto-generated profile, based on publicly available information

Sarah L. Dallas

Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City , 650 E 25th Street, Kansas City, MO 64108

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SDSarah L. Dallas
Sarah L. Dallas
JRJennifer L. Rosser
Jennifer L. Rosser
GMGregory R. Mundy
Gregory R. Mundy
LBLynda F. Bonewald
Lynda F. Bonewald
The binding of growth factors to the extracellular matrix (ECM) may be a key pathway for regulation of their activity. We have shown that a major mechanism for storage of transforming growth factor-β (TGF-β) in bone ECM is via its association with latent TGF-β-binding protein-1 (LTBP1). Although proteolytic cleavage of LTBP1 has been reported, it remains unclear whether this represents a physiological mechanism for release of matrix-bound TGF-β. Here we examined the role of LTBP1 in cell-mediated release of TGF-β from bone ECM. We first characterized the soluble and ECM-bound forms of latent TGF-β produced by primary osteoblasts. Next, we examined release of ECM-bound TGF-β by bone resorbing cells. Isolated avian osteoclasts and rabbit bone marrow-derived osteoclasts released bone matrix-bound TGF-β via LTBP1 cleavage. 1,25-Dihydroxyvitamin D3 enhanced LTBP1 cleavage, resulting in release of 90% of the ECM-bound LTBP1. In contrast, osteoblasts failed to cleave LTBP1 or release TGF-β from bone ECM. Cleavage of LTBP1 by avian osteoclasts was inhibited by serine protease and metalloproteinase (MMP) inhibitors. Studies using purified proteases showed that plasmin, elastase, MMP2, and MMP9 were able to cleave LTBP1 to produce 125–165-kDa fragments. These studies identify LTBP1 as a novel substrate for MMPs and provide the first demonstration that LTBP1 proteolysis may be a physiological mechanism for release of TGF-β from ECM-bound stores, potentially the first step in the pathway by which matrix-bound TGF-β is rendered active.

5 April 2010 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SDSarah L. Dallas
Sarah L. Dallas
LBLynda F. Bonewald
Lynda F. Bonewald

1 May 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SDSarah L. Dallas
Sarah L. Dallas
PSPitchumani Sivakumar
Pitchumani Sivakumar
CJCarolyn Jones
Carolyn Jones
QCQian Chen
Qian Chen
DPDonna M. Peters
Donna M. Peters
CKCay M. Kielty
Cay M. Kielty
Latent transforming growth factor-β-binding proteins (LTBPs) are extracellular matrix (ECM) glycoproteins that play a major role in the storage of latent TGFβ in the ECM and regulate its availability. Here we show that fibronectin is critical for the incorporation of LTBP1 and transforming growth factor-β (TGFβ) into the ECM of osteoblasts and fibroblasts. Immunolocalization studies suggested that fibronectin provides an initial scaffold that precedes and patterns LTBP1 deposition but that LTBP1 and fibronectin are later localized in separate fibrillar networks, suggesting that the initial template is lost. Treatment of fetal rat calvarial osteoblasts with a 70-kDa N-terminal fibronectin fragment that inhibits fibronectin assembly impaired incorporation of LTBP1 and TGFβ into the ECM. Consistent with this, LTBP1 failed to assemble in embryonic fibroblasts that lack the gene for fibronectin. LTBP1 assembly was rescued by full-length fibronectin and superfibronectin, which are capable of assembly into fibronectin fibrils, but not by other fibronectin fragments, including a 160-kDa RGD-containing fragment that activates α5β1 integrins. This suggests that the critical event for LTBP1 assembly is the formation of a fibronectin fibrillar network and that integrin ligation by fibronectin molecules alone is not sufficient. Not only was fibronectin essential for the initial incorporation of LTBP1 into the ECM, but the continued presence of fibronectin was required for the continued assembly of LTBP1. These studies highlight a nonredundant role for fibronectin in LTBP1 assembly into the ECM and suggest a novel role for fibronectin in regulation of TGFβ via LTBP1 interactions.

26 October 2017 in Aging
Verified
Journal Article
Open access
LTLeAnn M. Tiede-Lewis
LeAnn M. Tiede-Lewis
YXYixia Xie
Yixia Xie
MHMolly A. Hulbert
Molly A. Hulbert
RCRichard Campos
Richard Campos
MDMark R. Dallas
Mark R. Dallas
SDSarah L. Dallas
Sarah L. Dallas
Age-related bone loss and associated fracture risk are major problems in musculoskeletal health. Osteocytes have emerged as key regulators of bone mass and as a therapeutic target for preventing bone loss. As aging is associated with changes in the osteocyte lacunocanalicular system, we focused on the responsible cellular mechanisms in osteocytes. Bone phenotypic analysis was performed in young-(5mo) and aged-(22mo) C57BL/6 mice and changes in bone structure/geometry correlated with alterations in osteocyte parameters determined using novel multiplexed-3D-confocal imaging techniques. Age-related bone changes analogous to those in humans were observed, including increased cortical diameter, decreased cortical thickness, reduced trabecular BV/TV and cortical porosities. This was associated with a dramatic reduction in osteocyte dendrite number and cell density, particularly in females, where osteocyte dendricity decreased linearly from 5, 12, 18 to 22mo and correlated significantly with cortical bone parameters. Reduced dendricity preceded decreased osteocyte number, suggesting dendrite loss may trigger loss of viability. Age-related degeneration of osteocyte networks may impair bone anabolic responses to loading and gender differences in osteocyte cell body and lacunar fluid volumes we observed in aged mice may lead to gender-related differences in mechanosensitivity. Therapies to preserve osteocyte dendricity and viability may be beneficial for bone health in aging.

1 May 2019 in Bone
Verified
Journal Article
Closed access
LTLeAnn M. Tiede-Lewis
LeAnn M. Tiede-Lewis
SDSarah L. Dallas
Sarah L. Dallas

1 September 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
QCQian Chen
Qian Chen
PSPitchumani Sivakumar
Pitchumani Sivakumar
CBCraig Barley
Craig Barley
DPDonna M. Peters
Donna M. Peters
RGRonald R. Gomes
Ronald R. Gomes
SDSarah L. Dallas
Sarah L. Dallas
Latent transforming growth factor-β-binding proteins (LTBPs) are extracellular matrix (ECM) glycoproteins that play a major role in storage of latent TGF-β in the ECM and regulate its availability. We have previously identified fibronectin as a key molecule for incorporation of LTBP1 and TGF-β into the ECM of osteoblasts and fibroblasts. Here we provide evidence that heparan sulfate proteoglycans may mediate binding between LTBP1 and fibronectin. We have localized critical domains in the N terminus of LTBP1 that are required for co-localization with fibronectin in osteoblast cultures and have identified heparin binding sites in the N terminus of LTBP1 between residues 345 and 487. Solid-phase binding assays suggest that LTBP1 does not bind directly to fibronectin but that the binding is indirect. Heparin coupled to bovine serum albumin (heparin-BSA) was able to mediate binding between fibronectin and LTBP1. Treatment of primary osteoblast cultures with heparin or heparin-BSA but not with chondroitin sulfate impaired LTBP1 deposition onto fibronectin without inhibiting expression of LTBP1. Inhibition of LTBP1 incorporation was accompanied by reduced incorporation of latent TGF-β into the ECM, with increased amounts of soluble latent TGF-β. Inhibition of attachment of glycosaminoglycans to the core proteins of proteoglycans by β-d-xylosides also reduced incorporation of LTBP1 into the ECM. These studies suggest that heparan sulfate proteoglycans may play a critical role in regulating TGF-β availability by controlling the deposition of LTBP1 into the ECM in association with fibronectin.